80876-01-3
Chemical Structure
Indolapril
Synonym(s): CI-907
- CAS No.: 80876-01-3
- Formula:C24H34N2O5
- Molecular Weight:430.54
InChIKey: VXFJYXUZANRPDJ-MQBSTWLZSA-N
SMILES: CCOC([C@H](CCC1=CC=CC=C1)N[C@@H](C)C(N2[C@]3([H])[C@](CCCC3)([H])C[C@H]2C(O)=O)=O)=O
Biological Activity: Indolapril (CI-907) is an orally active angiotensin-converting enzyme (ACE) inhibitor with an IC50 value of 80 nM. Indolapril exerts a highly specific functional inhibitory effect on Ang I-mediated pressor/contractile responses, and its antihypertensive effect correlates with ACE inhibition in vascular tissues. Indolapril reduces blood pressure in multiple rodent and canine models of hypertension. Indolapril exists as a monoester prodrug and an active diacid form, and no side effects are observed in tested conscious animals. Indolapril is applicable to hypertension-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Indolapril | Indolapril (CI-907) is an orally active angiotensin-converting enzyme (ACE) inhibitor with an IC50 value of 80 nM. Indolapril exerts a highly specific functional inhibitory effect on Ang I-mediated pressor/contractile responses, and its antihypertensive effect correlates with ACE inhibition in vascular tissues. Indolapril reduces blood pressure in multiple rodent and canine models of hypertension. Indolapril exists as a monoester prodrug and an active diacid form, and no side effects are observed in tested conscious animals. Indolapril is applicable to hypertension-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Blankley CJ, et al. Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids. J Med Chem. 1987 Jun;30(6):992-8.
- [2]. Ryan MJ, et al. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor. The Journal of pharmacology and experimental therapeutics. 1984 Feb;228(2):312-8. [Content Brief]
